Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study

BACKGROUND: Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and treatment outcomes in treatment-eligible patients with COVID-19 receiving home-based care. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin Ju, Lee, Jacob, Seo, Yu Bin, Na, Sun Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840968/
https://www.ncbi.nlm.nih.gov/pubmed/36450290
http://dx.doi.org/10.3947/ic.2022.0123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840968/
https://www.ncbi.nlm.nih.gov/pubmed/36450290
http://dx.doi.org/10.3947/ic.2022.0123

Ejemplares similares